
LY2109761
CAS No. 700874-71-1
LY2109761( LY 2109761 | LY-2109761 )
Catalog No. M15688 CAS No. 700874-71-1
A potent, selective and orally active TGF-β RI/II dual inhibitor with Ki of 38/300 nM, respectively.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
2MG | 35 | In Stock |
![]() ![]() |
5MG | 58 | In Stock |
![]() ![]() |
10MG | 102 | In Stock |
![]() ![]() |
25MG | 178 | In Stock |
![]() ![]() |
50MG | 318 | In Stock |
![]() ![]() |
100MG | 480 | In Stock |
![]() ![]() |
200MG | 692 | In Stock |
![]() ![]() |
500MG | Get Quote | In Stock |
![]() ![]() |
1G | Get Quote | In Stock |
![]() ![]() |
Biological Information
-
Product NameLY2109761
-
NoteResearch use only, not for human use.
-
Brief DescriptionA potent, selective and orally active TGF-β RI/II dual inhibitor with Ki of 38/300 nM, respectively.
-
DescriptionA potent, selective and orally active TGF-β RI/II dual inhibitor with Ki of 38/300 nM, respectively; completely inhibits TGF-β-induced Sma2 phosphorylation on tumor cells or the liver microenviroment, inhibits the L3.6pl/GLT soft agar growth, suppresses both basal and TGF-β1-induced cell migration and invasion, and stimulates anoikis in vitro; significantly reduces the tumor burden as well as spontaneous abdominal metastases, and prolongs survival combined with gemicitabine in vivo model of pancreatic cancer.
-
In Vitro——
-
In Vivo——
-
SynonymsLY 2109761 | LY-2109761
-
PathwayTGF-beta/Smad
-
TargetTGFBR
-
RecptorTβRI|TβRII
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number700874-71-1
-
Formula Weight441.5249
-
Molecular FormulaC26H27N5O2
-
Purity>98% (HPLC)
-
Solubility10 mM in DMSO
-
SMILESN1(CCOC2=CC=C3C(C4=C(CCC5)N5N=C4C6=NC=CC=C6)=CC=NC3=C2)CCOCC1
-
Chemical NameQuinoline, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[2-(4-morpholinyl)ethoxy]-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Mazzocca A, et al. Hepatology. 2009 Oct;50(4):1140-51.
2. Zhang M, et al. Cancer Res, 2011, 71(23), 7155-7167.
3. Melisi D, et al. Mol Cancer Ther, 2008, 7(4), 829-840.
molnova catalog



related products
-
EW-7195
A novel potent and selective TGF-βRI (ALK5) inhibitor with IC50 of 4.83 nM.
-
VU 0469381
A potent, sellective BMP receptor ALK2 antaognist with Ki of 32 nM, with no affinity for ALK3/4/5/6.
-
DMH-1
DMH1 is a potent, selective bone morphogenetic protein receptor (BMP) inhibitor.